Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

Purpose: BIBF 1120 is an oral, potent angiokinase inhibitor targeting receptors of the vascular endothelial growth factors, platelet-derived growth factors, and fibroblast growth factors. This phase I, accelerated titration study assessed the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamic effects of BIBF 1120.

Patients And Methods: Sixty-one patients with advanced cancers received BIBF 1120 in successive cohorts.

Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.

Background: Accidental extravasation is a severe complication when administering anthracyclines. We describe 3 cases of extravasation with 3 different anthracyclines.

Patients And Methods: One patient came from another hospital for a second opinion after an epirubicin extravasation.